Argenica Therapeutics Reports Positive Results From Preclinical Study for Traumatic Brain Injury

MT Newswires Live

Feb 04

Argenica Therapeutics (ASX:AGN) said that its ARG-007 neuroprotective peptide drug candidate "significantly" reduced damage to brain cells caused by moderate traumatic brain injury in a preclinical rat study, according to a Tuesday Australian bourse filing.

The study assessed ARG-007 regarding the reduction of axonal injury and neuroinflammation seen following moderate traumatic brain injury and resulting behavioral outcomes.

It was found to protect brain cells in the injured brain by reducing axonal injury following injury, as measured by key axonal injury biomarkers neurofilament heavy protein and amyloid precursor protein.

The animals treated with the candidate also showed signs of improvement in a motor function test as well as a significant reduction in weight loss.

The data verifies data received from previous studies.

The firm's shares rose past 1% in recent trading on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2508107598"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508107598\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2508107598?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-04 12:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508107598","market":"hk","top_or_hot":-1,"title":"Argenica Therapeutics Reports Positive Results From Preclinical Study for Traumatic Brain Injury","media":"MT Newswires Live","content":"<html><body><p> Argenica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:AGN) said that its ARG-007 neuroprotective peptide drug candidate \"significantly\" reduced damage to brain cells caused by moderate traumatic brain injury in a preclinical rat study, according to a Tuesday Australian bourse filing.</p><p>The study assessed ARG-007 regarding the reduction of axonal injury and neuroinflammation seen following moderate traumatic brain injury and resulting behavioral outcomes.</p><p>It was found to protect brain cells in the injured brain by reducing axonal injury following injury, as measured by key axonal injury biomarkers neurofilament heavy protein and amyloid precursor protein.</p><p>The animals treated with the candidate also showed signs of improvement in a motor function test as well as a significant reduction in weight loss.</p><p>The data verifies data received from previous studies.</p><p>The firm's shares rose past 1% in recent trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argenica Therapeutics Reports Positive Results From Preclinical Study for Traumatic Brain Injury</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgenica Therapeutics Reports Positive Results From Preclinical Study for Traumatic Brain Injury\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-04 12:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Argenica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:AGN) said that its ARG-007 neuroprotective peptide drug candidate \"significantly\" reduced damage to brain cells caused by moderate traumatic brain injury in a preclinical rat study, according to a Tuesday Australian bourse filing.</p><p>The study assessed ARG-007 regarding the reduction of axonal injury and neuroinflammation seen following moderate traumatic brain injury and resulting behavioral outcomes.</p><p>It was found to protect brain cells in the injured brain by reducing axonal injury following injury, as measured by key axonal injury biomarkers neurofilament heavy protein and amyloid precursor protein.</p><p>The animals treated with the candidate also showed signs of improvement in a motor function test as well as a significant reduction in weight loss.</p><p>The data verifies data received from previous studies.</p><p>The firm's shares rose past 1% in recent trading on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2508107598","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508107598","pubTimestamp":1738642477,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Argenica Therapeutics  said that its ARG-007 neuroprotective peptide drug candidate \"significantly\" reduced damage to brain cells caused by moderate traumatic brain injury in a preclinical rat study, according to a Tuesday Australian bourse filing.The study assessed ARG-007 regarding the reduction of axonal injury and neuroinflammation seen following moderate traumatic brain injury and resulting behavioral outcomes.It was found to protect brain cells in the injured brain by reducing axonal injury following injury, as measured by key axonal injury biomarkers neurofilament heavy protein and amyloid precursor protein.The animals treated with the candidate also showed signs of improvement in a motor function test as well as a significant reduction in weight loss.The data verifies data received from previous studies.The firm's shares rose past 1% in recent trading on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK7096":"制药","BK4139":"生物科技","AGN.AU":"Argenica Therapeutics Ltd"},"translate_title":"Argenica Therapeutics报告创伤性脑损伤临床前研究的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"AGN.AU":0.9},"content_text":"Argenica Therapeutics (ASX:AGN) said that its ARG-007 neuroprotective peptide drug candidate \"significantly\" reduced damage to brain cells caused by moderate traumatic brain injury in a preclinical rat study, according to a Tuesday Australian bourse filing.The study assessed ARG-007 regarding the reduction of axonal injury and neuroinflammation seen following moderate traumatic brain injury and resulting behavioral outcomes.It was found to protect brain cells in the injured brain by reducing axonal injury following injury, as measured by key axonal injury biomarkers neurofilament heavy protein and amyloid precursor protein.The animals treated with the candidate also showed signs of improvement in a motor function test as well as a significant reduction in weight loss.The data verifies data received from previous studies.The firm's shares rose past 1% in recent trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}